Available in the UK through Grafton Optical, the Ocular Surface Analyser (OSA) offers a full assessment of the ocular surface through a combination of tests for dry eye diagnosis, from tear break up time to the tear volume production test. It allows the analysis of the Meibomian glands, as well as various measurements and classifications according to international grading scales.
To book an appointment at 100% Optical to demo the OSA or discuss with a member of the Grafton Optical team, please click here.
The OSA easily and efficiently integrates complex examinations such as meibography and tear film interferometry screening.
Dry Eye is commonly caused by Meibomian Gland Dysfunction (MGD). OSA shows the morphological changes in the glandular tissue and the system analysis of images obtained through the sensitive infrared camera (NIR) allows guided evaluation of:
• The presence and distribution of the Meibomian glands in the upper and lower eyelids
• The extension of the area with normal glands
• The percentage of the areas with or without altered glands
• The “absent” and “present” areas of different colour
Meibography, viewing the glands through trans-illumination of the eyelid with infrared light, allows the user to evaluate the morphology and drop out of the Meibomian Glands and to make an accurate MDG diagnosis.
The integrated software allows the user to analyse the functional and non-functional areas, and to evaluate the extension of the affected areas.
OSA provides complex lacrimal analysis that allows quick and detailed structural research of the tear composition. OSA makes it possible to identify the patient’s type of dry eye disease and determine which deficient layers (lipid, aqueous or mucin) should be treated.
To view the SBM Sistemi OSA video, please click here.
For a quote or to arrange a demo of the SBM Sistemi OSA or any other products please contact email@example.com or call us on +44 (0)1923 233980.
Grafton Optical is one of the UK's leading suppliers of ophthalmic instruments, equipping and servicing independent and larger chain opticians as well as Britain's hospitals.